Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1992-06-01
1994-10-11
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3170
Patent
active
053547730
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention is related to a novel method for the treatment of several bone affecting diseases, especially osteoporosis, which are characterized by loss of bone mass.
BACKGROUND OF THE INVENTION
The balance in normal subjects between on the one hand bone formation, which is associated with the number and activity of osteoblasts, that is cells associated with the production of bone in the organism, and on the other hand bone loss, which is associated with the number and activity of osteoclasts, that is cells associated with the absorption and removal of bone, is disturbed in several bone affecting diseases. At the present time there is no good treatment for any of these diseases, among which can be mentioned osteoporosis, Paget's disease of bone, hyperparathyroidism and related disorders, and several malignant neoplasms where tumor cells are producing osteoclast-activating factors and cause hypercalcemia.
Worldwide the most urgent need is for the treatment of osteoporosis and tumor associated hypercalcemia. In some areas, e.g. in England and in some other parts of Europe there is also high incidence of Paget's disease of bone.
In osteoporosis bone formation as well as bone resorption are disturbed, resulting in decreased bone mass. Osteoporosis predominantly affects the elderly, but also other groups such as postmenopausal women, where an estrogen deficit is believed to be a significant etiological factor, and immobilized patients. At this point it is not possible to clear up the whole picture of the disease mechanism and estimate which is the primary cause of osteoporosis. However, about 25% of osteoporotic females belong to what is called "rapid bone losers" and at least in those patients the bone resorption rate is probably increased. Landry and Fleisch showed in immobilization induced osteoporosis that bone resorption rate was accelerated, (Landry, M. and Fleisch, H,: The influence of immobilization on bone formation as evaluated the incorporation of tetracyclines. J. Bone Joint Surg. 46B: 764, 1964).
The clinical manifestations of osteoporosis comprise fractures, especially hip fractures, but also vertebral fractures and fractures of the proximal radius, and complication of such fractures.
In Finland it has been estimated that about 10% of all surgical hospital beds are used for the treatment of osteoporosis related fractures (Luthje, P.: Reisiluunkaulan ja trokantterin murtumapotilaiden hoito ja ennuste seka hiodon kustannukset. Thesis. Helsinki 1983).
The present methods for the treatment of osteoporosis include exercise; administration of estrogen, especially for postmenopausal women; and consumption of calcium or calcium containing material such as milk. Calcitonin, a hormone associated with calcium metabolism, has also been used in the treatment of osteoporosis. None of these methods of treating osteoporosis results in increase of the bone mass.
Several malignant tumors are known to be associated by hypercalcemia which is due to increased osteoclastic activity. This is a common complication for instance in the case of breast cancer and prostate cancer which are both one of the most common malignant tumors. Hypercalcemia is due to both systemic and local factors. Some malignant cells are known to secrete agents which stimulate bone resorption (Sato, K., Fujii, Y. Kachivehi, T., Kasono, K., Shizume, K.: Production of interleukin 1 alpha (IL-1.alpha.)-like activity and colony stimulating activity by clonal squamous cell carcinomas derived from patients with hypercalcemia and leucocytosis. In: Calcium Regulation and Bone Metabolism Vol. 9 (eds. D. V. Cohu, T. J. Martin, P. J. Meunier), 1986).
In malignant hypercalcemia calcitonin and diphosphonate treatment has been used.
Paget's disease (or osteitis deformans) of bone is a disease of unknown etiology where bone resorption and remodelling are increased leading sometimes even to the fractures of affected bone. Bone pain is the main indication of treatment in these patients. In these patients there is highly elevated
REFERENCES:
patent: 4558139 (1985-12-01), Hagenmaier
Kretschmer, A. "The Structures of Novel Insecticidal Macrolides: Bafilomycins D and E, and Oxohygrolidin", Agric. Biol. Chem., 49: 2509-2511, 1985.
Hensens et al. "Structure of the Sodium and Potassium Ion activated Adenosinetriphosphatase Inhibitor L-681,110" J. Am. Chem. Soc. 105: 3672-3679, 1983.
Meyer et al. "Bafilomycin-A.sub.1 -21-O-(.alpha.-L-rhamnopyranosid): Strukturaufklarung durch chemische Verknupfung mit Bafilomycin A.sub.1 und Leucanicidin" Helv. Chem. Acta. 68: 83-94, 1985.
Werner et al. "Metabolic Products of Microorganisms, 224 Bafilomycins, a New Group of macrolide Antibiotics Production, Isolation, Chemical Structure and Biological Activity" J. of Antibiotics 37: 110-117, 1984.
Wilton et al. "PD 118, 576: A New Antitumor Macrolide Antibiotic" J. of Antibiotics 38: 1149-1452, 1985.
Seto et al. "The Isolation and Structures of Hygrolidin Amide and Defumarylhygrolidin" J. Antibiotics 37: 610-613, 1984.
Geotz et al. "A new Antiparasitic Macrolide Fermentation, Isolation and Structure" J. Antibiotics 38: 161-168, 1985.
Corey et al. "Stereochemistry of the Hygrolidins" Tetrah. Let. 25: 4325-4325, 1984.
Kretschmer et al. "the Structure of Nover Insecticidal Macrolides: Bafilomycins D and E, and Oxohygrolidin- . . . " Agric. Biol. Chem. 49: 2509, 1985.
Reynolds, J. J. "Organ cultures of bone: Studies on the physiology and pathology of resorption". In: Organ culture in biomedical research, Bulls M., and Monnichendam eds. Cambridge University Press, pp. 355-366, 1976.
Herslof Margareta
Vaananen Kalervo
Wallmark Bjorn
Aktiebolaget Astra
Cintins Marianne M.
Criares T. J.
LandOfFree
Use of bafilomycine and derivatives to treat bone diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of bafilomycine and derivatives to treat bone diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of bafilomycine and derivatives to treat bone diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1658869